News

The Manila Times23m
Ocular Therapeutix™ Reports First Quarter 2025 Results and Business Highlights
Research and development expenses for the first quarter of 2025 were $42.9 million versus $20.7 million for the comparable ...
The Manila Times24m
Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab)
The U.S. FDA has approved SELARSDI™ (ustekinumab-aekn) as interchangeable with the reference biologic Stelara® (ustekinumab) ...